Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$116.19 USD

116.19
36,083

+0.21 (0.18%)

Updated Sep 20, 2024 09:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novartis Wins FDA Approval of Kisqali for Early Breast Cancer

by Zacks Equity Research

The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.

Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%

by Zacks Equity Research

NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.

Why Novartis (NVS) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Lilly Gets FDA Approval for Eczema Drug Ebglyss

by Zacks Equity Research

The FDA approves Lilly's Ebglyss based on data from ADvocate 1, ADvocate 2 and ADhere studies.

Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq

by Zacks Equity Research

The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.

Ahan Chakraborty headshot

Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks

by Ahan Chakraborty

Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals

by Zacks Equity Research

This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.

Relay Stock Soars on Upbeat Data From Breast Cancer Study

by Zacks Equity Research

RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC.

Bayer Reports Encouraging NSCLC Drug Data, Gets Approval for Eylea 8mg

by Zacks Equity Research

BAYRY's NSCLC drug BAY 2927088 shows an encouraging safety profile in the expansion part of the ongoing study. The company also announces the approval of Eylea 8mg.

Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug

by Zacks Equity Research

The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and congenital disabilities.

Novartis to License VYGR's Capsid for Gene Therapy in Neurology

by Zacks Equity Research

NVS has decided to license a novel capsid generated from Voyager's TRACER platform for use in a gene therapy program against an undisclosed rare neurologic disease target.

NVS or LLY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

NVS vs. LLY: Which Stock Is the Better Value Option?

Novartis (NVS) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Novartis (NVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Terns Surges 29.6% in Three Months: Will the Momentum Continue?

by Zacks Equity Research

TERN has outperformed the industry in the past three months on encouraging pipeline progress of its candidates. Positive data on obesity candidates should boost the stock further.

Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study

by Zacks Equity Research

NVS' late-stage study meets its primary endpoints, demonstrating the superiority of Leqvio monotherapy over both placebo and ezetimibe in LDL-C reduction.

Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition

by Zacks Equity Research

Alnylam's (ALNY) Amvuttra and Givlaari sales continue to boost revenues. However, its reliance on collaboration partners and stiff competition remain concerns.

Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug

by Zacks Equity Research

Incyte???s (INCY) late-stage study on tafasitamab for patients with relapsed or refractory follicular lymphoma meets its goal. FDA approves axatilimab for the treatment of chronic graft-versus-host disease.

Sundeep Ganoria headshot

Medicare Releases Negotiated Prices on 10 Expensive Drugs

by Sundeep Ganoria

Following negotiations between Medicare and participating drug companies, some of the world's biggest medicines will see price cuts of 38-79%. These lowered prices will be going into effect in 2026.

Novartis' (NVS) Motion to Block Entresto Generic Denied: What's Next?

by Zacks Equity Research

Novartis' (NVS) efforts to ward off generic competition for its top cardiovascular drug, Entresto, face a setback.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, MRK's New Deal & Other Updates

by Kinjel Shah

Eli Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce second-quarter results. Merck (MRK) expands existing co-development deal with partner Daiichi Sankyo.

Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues

by Zacks Equity Research

Alnylam (ALNY) gains 13% on upbeat second-quarter results, beating both earnings and revenue estimates, primarily driven by higher collaboration revenues from Regeneron and strong Amvuttra sales.

Incyte's (INCY) Q2 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Incyte's (INCY) second-quarter 2024 earnings miss estimates while revenues beat the same. The company raises the bottom end of the 2024 revenue guidance for its lead drug, Jakafi.

Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?

by Zacks Equity Research

On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.